# Pizarra — PT-pseudo_d217629c323a (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d217629c323a
Task: 1

Encounter: Urology - outpatient on 08 Jan 2025.
Referrer: Dr. S. de Vries (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 3.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.126 ng/mL²
  - PSA velocity: 1.39 ng/mL/yr
  - Prior PSA: 2.6 ng/mL
  - Prostate volume: 30.21 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.79094493 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 3.8 ng/mL. PI-RADS 4. PSAD 0.13. Prostate volume 30 mL. DRE nodus. csPCa 0.79.

Vitals: weight 83 kg, height 183 cm, BMI 24.8, BP 102/63 mmHg, HR 88 bpm. Smoking: Non-smoker.

Chief complaint: Routine monitoring for a previously identified Gleason 3+4 lesion alongside a recent PSA increase to 3.8 ng/mL.

History: A seventy-year-old retired postal worker, married and living with his partner, attends for ongoing surveillance of a previously diagnosed Gleason 3+4 focus. Current laboratory data shows a PSA elevation to 3.8 ng/mL. This gentleman is a non-smoker, maintains a robust routine that includes biweekly tennis matches, and limits alcohol intake to roughly six standard drinks weekly. Lower urinary tract complaints are negligible, reflected by an IPSS score of 2, with explicit denial of haematuria or erectile difficulties. Ophthalmic history includes bilateral cataract removal three years back, necessitating large-print materials for mild visual deficits, alongside a recent dental screening. Systemic review reveals no unexplained weight reduction, skeletal discomfort, or constitutional complaints. Concurrently, no comorbid conditions or active pharmacological agents are recorded.

Physical examination: DRE reveals a gland measuring approximately 30 mL, characterized by a firm, discrete nodule within the right lobe. The remaining prostatic tissue exhibits symmetry without tenderness, and palpation of the inguinal regions detects no lymphadenopathy. Vital parameters remain stable, with general survey showing no evidence of systemic pathology.

Patient info: retired postal worker; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 6 units / week; exercise Tennis 2x/week; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.72 +/- 0.23   (95% CI 0.28-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.23  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.86 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value of 3.8 ng/mL?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral, as the visible panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the context that the patient has a prior positive biopsy, which fundamentally changes the question from "does he have cancer?" to "is the current finding progression or recurrence?" Specifically, the prior did not weigh the specific PI-RADS 4 score against the prior positive biopsy status, nor did it weigh the rising PSA velocity (1.39 ng/mL/yr) in conjunction with the prior positive diagnosis.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.72) despite the guideline criterion stating the panel is insufficient. This is wrong because the prior failed to account for the guideline's explicit instruction that the decision *must* come from the retrieved documents (MRI, PSA trend, previous notes), which are currently missing. Furthermore, the prior's high aleatoric uncertainty (H=0.86) suggests the model cannot distinguish between the 'biopsy' and 'defer' options given the input, which is precisely what the EXPERT-PROTOCOL stated.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value of 3.8 ng/mL?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Catharina Ziekenhuis, Eindhoven | 05 Jan 2025 | Multiparametric MRI Prostate
The MRI shows a 12 mm focal hypointense lesion in the right mid-gland with PI-RADS 4. No extraprostatic extension or seminal vesicle invasion is observed.
get_psa_trend
PSA trend shows values: Sep 2022: 0.6 ng/mL, Nov 2023: 1.5 ng/mL, Jan 2025: 3.8 ng/mL.
get_previous_notes
18 Jul 2023: Initial PSA elevation to 1.3 ng/mL was documented in September 2022, with subsequent surveillance tracking a climb to 2.6 ng/mL by November 2023. Surveillance warranted a urology referral for comprehensive evaluation and biopsy deliberation.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents did not raise a specific question requiring this panel (e.g., free-PSA fraction or renal function before invasive procedure).

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion (12 mm) noted, suggesting a potentially significant lesion.
- PSA trend: Rising trend from 0.6 ng/mL (Sep 2022) to 3.8 ng/mL (Jan 2025), indicating progression.
- Previous notes: Prior biopsy was positive, and surveillance was initiated based on rising PSA.

AGAINST sampling this patient now:
- Previous notes: The prior biopsy result is documented, which is the primary context for the decision.

WHERE THIS LEANS
The retrieved evidence strongly suggests progression given the rising PSA trend and the presence of a PI-RADS 4 lesion, which aligns with the need for re-evaluation as per the protocol.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (rising PSA trend and PI-RADS 4 lesion combined with a prior positive biopsy) strongly leans towards a biopsy, satisfying the requirement set by the EXPERT-PROTOCOL that the decision must come from the retrieved documents.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans towards biopsy because the retrieved evidence showed progression, specifically the rising PSA trend from 0.6 ng/mL to 3.8 ng/mL and the presence of a PI-RADS 4 lesion. This finding, combined with the prior positive biopsy status, satisfies the need to re-evaluate the known disease. The statistical prior suggested biopsy, and the retrieved documents confirmed the clinical need for further tissue sampling.

Variables that carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
